Google
Trusted Resources: News & Events
Latest announcements and gatherings
Long-term opioids may not be best pain management option for all sickle cell patients
Small study shows some on opioids reported more pain, fatigue.
In a small study looking at pain assessments in adults with sickle cell disease, researchers at Johns Hopkins says overall, those treated long-term with opioids often fared worse in measures of pain, fatigue and curtailed daily activities than those not on long-term opioids.
In a report on the new research, published online on June 15 in a special sickle cell disease supplement of the American Journal of Preventive Medicine, C. Patrick Carroll, M.D., and colleagues evaluated pain experiences of participants with sickle cell disease who were prescribed long-term opioids.
+myBinderRelated Content
-
Crizanlizumab lowers pain crises in at-risk sickle cell patients, ad-hoc trial data showNovartis’ investigational th...
-
Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and...Background: In the Dominican Republic,...
-
The effects of relaxation intervention on pain, stress, and autonomic responses among adults with sickle cell pain i...Pain is the major complication for the a...
-
L-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
-
Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
-
Today’s Faces of Sickle Cell Disease: Jennelle StephensonJennelle Stephenson was diagnosed with S...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.